RxDoctor Payments Data

Adil Asaduddin, MD

Internal Medicine · Houston, TXNPI 1538199708

Payments from drug & device makers

$8,260in general payments, 2019–2025

Across 466 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$788
  • Boehringer Ingelheim$538
  • GSK$512
  • Lilly USA, LLC$503
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,17199%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,260 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$312,773
Medicare patients
525
Services billed
2,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$202,696
MounjaroTirzepatide47$85,209
EliquisApixaban49$47,123
Synjardy XrEmpagliflozin/Metformin Hcl26$38,156
FarxigaDapagliflozin Propanediol34$32,844
JardianceEmpagliflozin20$29,875
XareltoRivaroxaban28$28,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$27,512
Xigduo XrDapaglifloz Propaned/Metformin24$25,730
MyrbetriqMirabegron26$24,636
JanuviaSitagliptin Phosphate18$19,915
VascepaIcosapent Ethyl16$11,582
Tresiba Flextouch U-200Insulin Degludec13$11,257
Icosapent Ethyl11$8,514
SynthroidLevothyroxine Sodium53$4,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,067$202,696106 claims
Lilly USA, LLCMounjaro$503$85,20947 claims
Boehringer IngelheimSynjardy Xr, Jardiance$538$68,03146 claims
PfizerEliquis$389$47,12349 claims
AstraZenecaFarxiga$788$32,84434 claims
Johnson & JohnsonXarelto$61$28,16828 claims
GSKTrelegy Ellipta$512$27,51228 claims
Astellas Pharma US IncMyrbetriq$89$24,63626 claims
MerckJanuvia$66$19,91518 claims
AbbVieSynthroid$1,562$4,15053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →